In Brief: Teva Copaxone
Executive Summary
Teva Copaxone: Copolymer-1 (NDA 20-622) for patients with exacerbating-remitting multiple sclerosis will be reviewed by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on Sept. 19. The meeting will begin at 8:30 a.m. at the Holiday Inn in Gaithersburg, Md. The meeting originally was scheduled for Sept. 16-17 ("The Pink Sheet" July 22, T&G-1)...